Risk Markers in the Acute Coronary Syndromes (RACS)
The main aim of this trial is to assess the long-term prognostic value of different types of Factor XIIa in an unselected, single center series of 871 chest pain patients admitted to the emergency unit, employing blood samples collected at admission.
The second purpose of this study is to assess the incremental prognostic value of B-type natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP).
A third purpose of this study is to evaluate the prognostic impact of the Omega-3 Index which is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to other fatty acids in the erythrocyte membrane.
Coronary Artery Disease
Unstable Angina Pectoris
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.|
- Total Mortality. [ Time Frame: 24 months. ] [ Designated as safety issue: No ]
- Recurrent Troponin-T (TnT) Positive Events [ Time Frame: 24 months. ] [ Designated as safety issue: No ]Recurrent Troponin-T (TnT) positive events; Symptoms of coronary ischemia associated with TnT >0.05 ng/mL with a pattern of gradual rise and fall in TnT
Biospecimen Retention: Samples Without DNA
Serum, Citrated plasma, EDTA-plasma and packed red blood cells are kept in suitable aliquots at -80 degrees Celcius.
|Study Start Date:||November 2002|
|Study Completion Date:||December 2005|
|Primary Completion Date:||December 2005 (Final data collection date for primary outcome measure)|
Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00521976
|Stavanger University Hospital|
|Stavanger, Rogaland, Norway, 4068|
|Principal Investigator:||Dennis WT Nilsen, MD PhD FESC||Stavanger University Hospital, Dept. of Cardiology|